生物制剂治疗克罗恩病的研究进展

Advances in the study of biological agents in the treatment of Crohn’s disease

克罗恩病(Crohn's disease,CD)是一种可累及全消化道的慢性非特异性肠道炎性疾病。大量临床试验证明生物制剂对CD的诱导缓解有效,维持治疗可获得疾病长期缓解。目前生物制剂已广泛应用于CD的治疗,成为该病的主要治疗方式,如抗肿瘤坏死因子-α单克隆抗体、抗整合素单克隆抗体、抗IL-12/23单克隆抗体、Janus激酶抑制剂等。本文就生物制剂治疗CD的研究进展及其应用作一综述。

Crohn’s disease(CD)is a chronic,non-specific intestinal inflammatory disease.A large number of clinical trials have shown that biological agents are effective in inducing remission in patients with CD,and maintenance treatment can achieve long-term remission.At present,biological agents are now being widely used in the treatment of CD and have become the main treatment.These include the anti-tumor necrosis factor(TNF)-αmonoclonal antibodies,anti-integrin antibody,IL-12/23 monoclonal antibody and a Janus kinase(JAK)inhibitor.In this article,we review the progress and selection of biologics in the treatment of CD.